SPIRO(CYCLOHEXANE-1,3'(1'H)-FURO(3,4-C)PYRIDINE)-4-CARBOXAMIDE, N-(1-(2-FLUOROPHENYL)-1H-PYRAZOL-3-YL)-1'-OXO-, TRANS-
Obesity
Merck Sharp & Dohme LLCSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 59/ 100
Competitive context
575 Active assets in the Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
vi-0521 VIVUS LLC | Phase 4 | BBB |
Phentermine Russell McCulloh, MD | Phase 4 | BBB |
Deoxycholic Acid University of California, San Diego | Phase 4 | BBB |
asc30 Ascletis Pharma (China) Co., Limited | Phase 2 | BBB |
Efsubaglutide Alfa The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
SPIRO(CYCLOHEXANE-1,3'(1'H)-FURO(3,4-C)PYRIDINE)-4-CARBOXAMIDE, N-(1-(2-FLUOROPHENYL)-1H-PYRAZOL-3-YL)-1'-OXO-, TRANS- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →